

Europass curriculum vitae

INFORMAZIONI PERSONALI

Nome

CLAUDIA PROTO

Data di nascita

15/09/1983

ESPERIENZA LAVORATIVA

Date

Dal 01 Giugno 2019 a tutt'oggi

Posizione

Dirigente medico in Oncologia Medica

Principali mansioni e responsabilità

Attività di reparto, di ambulatorio e di day-hospital in Oncologia Medica

Aree di interesse: Oncologia Medica Toracica (tumori polmonari, mesoteliomi pleurici, tumori ad origine timica). Gestione dell'iter diagnostico-terapeutico: diagnosi e stadiazione di malattia. Uso di chemioterapia, agenti biologici, immunoterapia e terapie di supporto. Gestione di trials clinico-sperimentali. Ricerca traslazionale.

Datore di Lavoro

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano – UO Oncologia Medica 1, Direttore Prof. F. de Braud

Date

Dal 21 Novembre 2014 al 31 Maggio 2019

Posizione

Medico Oncologo (Collaborazione Libero Professionale)

Principali mansioni e responsabilità

Attività di reparto, di ambulatorio e di day-hospital in Oncologia Medica

Aree di interesse: Oncologia Medica Toracica (tumori polmonari, mesoteliomi pleurici, tumori ad origine timica). Gestione dell'iter diagnostico-terapeutico: diagnosi e stadiazione di malattia. Uso di chemioterapia, agenti biologici, immunoterapia e terapie di supporto. Gestione di trials clinico-sperimentali. Ricerca traslazionale.

Datore di Lavoro

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano – UO Oncologia Medica 1, Direttore Prof. F. de Braud

Date

Dal 30 Giugno 2009 al 30 Giugno 2014

Posizione

Medico in formazione specialistica della Scuola di Specializzazione in Oncologia

Principali mansioni e responsabilità

Attività di reparto in Medicina Interna per 7 mesi. Attività di reparto, di ambulatorio e di day-hospital in Oncologia Medica. Periodi di training in: Biologia Molecolare (estrazione e sequenziamento DNA e RNA, RT-PCR, colture cellulari), Anatomia Patologica (esame macroscopico e microscopico di campioni chirurgici, Immunoistochimica, FISH), Radiologia (ecografia, mammografia, TC, RM), Radioterapia, Chirurgia Generale, Anestesia.

Aree di interesse: tumori polmonari, tumori del distretto cervico-facciale, tumori del sistema nervoso centrale, tumori mammari, tumori ginecologici e melanomi. Esperienza nell'uso di chemioterapia e agenti biologici, terapie di supporto, trials clinici e ricerca traslazionale.

Datore di Lavoro	Scuola di Specializzazione in Oncologia - Università degli Studi di Messina c/o AOOR Papardo-Piemonte – UOC Oncologia Medica, Direttore Prof.V. Adamo – Messina. Tesi di Specializzazione in Oncologia: <i>“Approccio terapeutico integrato e caratterizzazione biomolecolare nel trattamento del carcinoma squamoso della testa e del collo: esperienza di tre aree metropolitane”.</i>
Qualifica conseguita Livello nella classificazione nazionale	Medico Specialista in Oncologia 50/50 e lode
Date Posizione	Da Luglio 2009 a Novembre 2014 Medico Sostituto presso Presidi di Continuità Assistenziale
Datore di Lavoro	Servizio Sanitario Nazionale – ASP 5, Messina
Date Posizione	Da Luglio 2009 a Novembre 2014 Medico Sostituto di Medicina Generale
Datore di Lavoro	Studio Medico di Medicina Generale Dott. Umberto Mammola, via Placida n°84, Messina
ISTRUZIONE E FORMAZIONE	
Date	Febbraio 2009
Nome e tipo di istituto di istruzione	Università degli Studi di Messina- Facoltà di Medicina e Chirurgia
Qualifica conseguita	Abilitazione all'esercizio della professione di Medico Chirurgo , regolarmente iscritta all' Ordine dei Medici Chirurghi della Provincia di Messina
Livello nella classificazione nazionale	270/270
Date	Da Gennaio 2005 a Ottobre 2008
Nome e tipo di istituto di istruzione	Università degli Studi di Messina - AOU Policlinico “G. Martino”, UOC Terapie Integrate in Oncologia, Dir. Prof. Vincenzo Adamo
Posizione	Studente in medicina frequentatore
Principali materie/abilità professionali oggetto dello studio	Prevenzione, diagnosi, stadiazione e trattamento medico (adiuvante, neoadiuvante e metastatico) delle neoplasie maligne; ricerca e trials clinici; terapie di supporto e gestione di pazienti terminali.
Qualifica conseguita	<i>Training in Oncologia Medica</i>
Date	Da Ottobre 2002 a Ottobre 2008
Nome e tipo di istituto di istruzione	Università degli Studi di Messina- Facoltà di Medicina e Chirurgia

Posizione	Studente in Medicina
Principali materie/abilità professionali oggetto dello studio	Biologia e genetica, anatomia umana, fisiologia umana, fisiopatologia delle malattie umane, anatomia patologica, diagnostica per immagini e radioterapia, farmacologia, oncologia clinica ed ematologia, chirurgia generale, medicina interna Tesi di Laurea in Oncologia: <i>"Ruolo della terapia a bersaglio molecolare nel trattamento del tumore del polmone NSC avanzato. Nostra esperienza con erlotinib".</i>
Qualifica conseguita	Laurea specialistica in Medicina e Chirurgia
Livello nella classificazione nazionale	110/110 e lode
Date	Dall'anno scolastico 1997/1998 all'anno scolastico 2001/2002
Nome e tipo di istituto di istruzione	Liceo Classico "Vittorio Emanuele", Patti (ME)
Posizione	Studente
Principali materie oggetto dello studio	Italiano, Inglese, Latino, Greco, Biologia, Matematica, Fisica, Storia, Filosofia
Qualifica conseguita	Diploma di Maturità Classica
Livello nella classificazione nazionale	100/100
Date	2001
Nome e tipo di istituto di istruzione	Trinity College – London
Qualifica conseguita	Certificate of Spoken English for Speakers of Other Languages
CAPACITÀ E COMPETENZE PERSONALI	
MADRELINGUA	Italiano
ALTRE LINGUE	Inglese
Capacità di lettura	eccellente
Capacità di scrittura	ottimo
Capacità di espressione orale	ottimo
CAPACITÀ E COMPETENZE RELAZIONALI ED ORGANIZZATIVE	Socio AIOM (Associazione Italiana di Oncologia Medica), ESMO (European Society for Medical Oncology) Ottima capacità di relazione e lavoro in équipe. Abilità nella gestione delle attività di sperimentazione clinica e di progetti di ricerca clinica e traslazionale Competenza nell'approccio clinico ed umano al paziente oncologico
Page 3 - Curriculum vitae di Claudia Proto	

Premio "Fondazione Guido Berlucci Miglior Poster" per ricercatori in oncologia c/o laboratori Italiani, sotto i 35 anni di età, che verrà conferito in occasione del XVIII congresso Nazionale AIOM (Roma, 28 - 30 Ottobre 2016) per il lavoro dal titolo "SMO MUTATIONS ROLE IN MALIGNANT PLEURAL MESOTHELIOMA: A NEGATIVE PROGNOSTIC FACTOR, BUT POSSIBLE NEW TARGET?"

CAPACITÀ E COMPETENZE TECNICHE

Ottima capacità d'utilizzo del PC (Word, Power Point, Outlook, Internet, Excel) e di ricerca in database

PATENTE O PATENTI

Patente di categoria B

ULTERIORI INFORMAZIONI PUBBLICAZIONI SCIENTIFICHE :

Abstracts:

1. **C. Proto**, A. Prelaj, C. Verri, D. Signorelli, G. Lo Russo, R. Ferrara, G. Galli, B. Trevisan, M. Mavis, F. G. De Braud, MC. Garassino, G. Sozzi, M. Boeri. A plasma miRNA signature classifier identifies PD-L1 $\geq$ 50% NSCLC nonresponders to immune checkpoint inhibitors. [Accepted as poster at ASCO 2019]
2. D Signorelli, R Ferrara, **C Proto**, G Lo Russo, M Imbimbo, G Galli, A De Toma, F Pagani, G Randon, G Fucà, B Trevisan, M Ganzinelli, N Zilembo, A Fabbri, F G. De Braud, MC Garassino, A Prelaj. Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology. [Accepted as poster at ASCO 2019]
3. Galli G, Corsetto PA, Ferrara R, Prelaj A, **Proto C**, Signorelli D, Zilembo N, De Toma A, Pagani F, Randon G, Ganzinelli M, Sica A, de Braud F, Garassino MC, Lo Russo G. Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy. [Accepted as abstract at ASCO 2019]
4. Prelaj A, Lo Russo G, **Proto C**, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Zilembo N, Trevisan B, Montrone M, Longo V, Pesola F, Varesano N, Del Bene G, Pizzutilo P, Galetta D, Garassino MC, Di Maio M, Catino AM. Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation. [Accepted as abstract at ASCO 2019]
5. Galli G, **Proto C**, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Randon G, Trevisan B, Ganzinelli M, Ganzinelli M, Garassino MC, Lo Russo G. Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy. ELCC 2019.
6. Prelaj A, Lo Russo G, Signorelli D, Ferrara R, Imbimbo M, Galli G, De Toma A, Randon G, Brambilla M, Trevisan B, Ganzinelli M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, **Proto C**. EPSiLoN score: validation color of a prognostic score in advanced non-small cell lung cancer (Anslc) patients treated with immunotherapy. ELCC 2019
7. Galli G, Poggi M, Fucà G, Imbimbo M, Lo Russo G, **Proto C**, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Vitali M. Effect of basal lymphopenia on outcome of non small cell lung cancer patients treated with immunotherapy." [Poster at WCLC 2018].
8. Galli G, Poggi M, Fucà G, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino M, Lo Russo G. Impact of antibiotics on outcome of metastatic non small cell lung cancer patients treated with immunotherapy." [Mini Oral Presentation at WCLC 2018].
9. G. Sozzi, M. Sommariva, M. Moro, **C. Proto**, D. Signorelli, M. Ganzinelli, S. Sangaletti, M. Boeri, G. Lo Russo, S. Ferro, E. Tassi, V. Huber, L. Sfondrini, M. Milione, C. Tripodo, M. Colombo, A. Anichini, A. Balsari, L. Rivoltini, M. Garassino. PD-1 blockade promotes hyperprogressive disease in NSCLC through macrophages activation via antibody Fc/FcR interaction. [Mini Oral Presentation at WCLC 2018].
10. M. Boeri, M. Milione, D. Signorelli, C. **Proto**, G. Lo Russo, C. Galeone, G. Centonze, U. Pastorino, M. Garassino, G. Sozzi. MicroRNA-based liquid biopsy combines with PD-L1

- tumor expression to predict response to immunotherapy in advanced NSCLC patients. [Mini Oral Presentation at WCLC 2018].
11. G. Fucà, M. Poggi, G. Galli, M. Imbimbo, G. Lo Russo, **C. Proto**, M. Vitali, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, D. Signorelli. Effect of early steroids use in advanced NSCLC patients treated with immunotherapy. [Mini Oral Presentation at WCLC 2018].
 12. Galli G, Botta L, Poggi M, Fuca' G, Imbimbo M, Lo Russo G, **Proto C**, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino MC., Signorelli D. Concomitant immunotherapy and radiotherapy for metastatic non small cell lung cancer: a single Institution experience. PO-STER AIOM 2018
 13. G Fucà, M Poggi, G Galli, M Imbimbo, G Lo Russo, **C Proto**, D Signorelli, M Ganzinelli, N Zilembo, F de Braud, M C Garassino, Vitali F. Prognostic and predictive role of Hyponatremia in patients with metastatic non small cell lung cancer treated with immunotherapy. POSTER AIOM 2018
 14. Galli G, Poggi M, Fucà G, Lo Russo G, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, Filippo de Braud F, Garassino MC, Imbimbo M. Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer. ESMO 2018 Congress, 19-23 October, Munich, Germany.
 15. Galli G, Poggi M, Fucà G, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, Filippo de Braud F, Garassino MC, Lo Russo G. Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer. POSTER 3033. ESMO 2018 Congress, 19-23 October, Munich, Germany.
 16. G Fucà, M Poggi, G Galli, M Imbimbo, G Lo Russo, D Signorelli, M Vitali, M Ganzinelli, N Zilembo, F de Braud, M C Garassino, **C Proto**. Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors. POSTER 1389P. ESMO 2018 Congress, 19-23 October, Munich, Germany. Ann Oncol; 29: 8.
 17. Galli G, Lo Russo G, **Proto C**, Signorelli D, Vitali M, Botta L, Imbimbo M, Zilembo N, Garassino M. Potential synergy of immunotherapy and radiotherapy in patients with metastatic non small cell lung cancer: a single Institution experience." [Poster at IASLC Immunotherapy 2018 on 27/03/2018].
 18. D Cortinovis, A Delmonte, R Chiari, A Catino, F Grossi, C Noberasco, F Gelsomino, M Gilli, **C Proto**, H Soto Parra, M R Migliorino, L Bonomi, D Tassinari, A Frassoldati, V Albanese, G Fadda, F De Galitiis, G Finocchiaro, F Cognetti. Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases. P3.02c-094. JTO Volume 12, Issue 1, Supplement, January 2017, Page S1336
 19. Imbimbo M, **Proto C**, Mallone S, Signorelli S, Greco FG, Calareso G, Botta L, Lo Russo G, Vitali M, Corrao G, Galli G, Ganzinelli M, Zilembo N, Pastorino U, Garassino MC, Trama A. TNM or tumor volume for predicting prognosis in malignant pleural mesothelioma: still an open debate. Poster IASLC WCLC 2017. Yokohama, Japan 15-18/10/2017.
 20. Signorelli D, Cona MS, Vitali M, Lo Russo G, **Proto C**, Imbimbo M, Zilembo N, Platania M, Del Vecchio M, Seregini M, Garassino MC, Di Nicola MA, De Braud FG. Correlation between dysthyroidism and efficacy in patients treated with anti PD-1 or anti PDL-1 agents. Meeting 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. Citation: J Clin Oncol 35, 2017 (suppl 7S; abstract 67)
 21. Trama A, Botta L, Signorelli D, **Proto C**, Gennaro V, Benfatto L, Lando CF, Mensi C., Dallari B, Consonni D, Merler E, Bressan V, Mirabelli D, Gangemi M, Brentisci C, Stura A, Romanelli A, Storchi C, Chellini E, Cocchioni M, Pascucci C, La Rosa F, Petrucci MS, Ascoli V, Angelillo IF, Feola D, Tumino R, Tagliabue G, Contiero P, Gola G, Corti M, Fanetti AC, Crocetti E, Caldarella A, Sciacca S., Bella F, Cusimano R, Amodio R, Ziino A, Candela P, Scuderi T, Frasca G, Giurdanella MC, Cirilli C, Michiara M, Rimanti A., Tiseo M, De Giorgi AM, Sgargi P, Mangone L, Vicentini M, Falcini F, Giuliani O, Vattiato R, Fusco M, Vitale MF, Piffer S, Rizzello RV, Piro R, Forastiere F, Romeo E, De Angelis R, Capocaccia R, Mallone S, Foschi R, Gatta G., Garassino MC. Malignant pleural mesothelioma long-term survivors: a population based study (LUME study). iMig 2016

22. Botta L, Trama A, **Proto C**, Signorelli D, Garassino MC, Capocaccia R, Gatta G. Malignant pleural mesotelioma long-term survivors: a population based study (LUME study). GRELL 2016
23. **Proto C**, Signorelli D, Mallone S, Greco FG, Calareso G, Botta L, **Lo Russo G**, Imbimbo M, Vitali M, Ganzinelli M, Zilembo N, Platania M, Pastorino U, Garassino MC, Trama A. Study comparing volume and TNM in predicting clinical outcome in Malignant Pleural Mesothelioma. Poster WCLC 2016.
24. Agustoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Lo Russo G, Signorelli D, **Proto C**, Vitali M, Imbimbo M, Zilembo N, Garassino M, Procopio G, De Braud F, Morelli D, Platania M. Impact of hyponatremia in a tertiary cancer center: A one-year-survey at National Cancer Institute of Milan. Poster AIOM 2016
25. **Proto C**, Ganzinelli M, Botta L, Tiseo M, Pasello G, Fabbri A, Lo Russo G, Trama A, Imbimbo M, Vitali M, Macerelli M, Zilembo N, Gallucci R, Brissa A, Platania M, Zaffaroni N, Serafini MS, de Braud F, Garassino MC, Signorelli D. SMO mutations role in Malignant Pleural Mesothelioma: a negative prognostic factor, but possible new target? Poster AIOM 2016, Premio Berlucci.
26. F. Grossi, L. Crinò, A. Misino, P. Bidoli, A. Delmonte, F. Gelsomino, **C. Proto**, M. Mancini, L. Landi, D. Turci, S. Quadri, P. Antonelli, P. Marchetti, L. Toschi, S. Giusti, F. Di Costanzo, F. Rastelli, P. Sandri, V. Scotti, F. de Marinis. Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. *Annals of Oncology* 27 (Supplement 6): vi359–vi378, 2016
27. Agustoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Dotti K, Morano F, Lo Russo G, Signorelli D, **Proto C**, Vitali M, Imbimbo M, Zilembo N, Garassino M, De Braud F, Platania M. 1469P - Impact of hyponatremia in a tertiary cancer center: A one-year-survey at National Cancer Institute of Milan. Poster E-SMO 2016.
28. Signorelli D, **Proto C**, Ganzinelli M, Lo Russo G, Botta L, Trama A, Pasello G, Tiseo M, Pelosi G, Garassino M. SMO mutation is a strong negative prognostic factor in malignant pleural mesotelioma. *J Thorac Oncol* 2016 11 (4): S57-S166. S1556-0864(16)X0004-4. Poster ELCC 2016 (SU PUBMED)
29. Signorelli D, Cona MS, Lo Russo G, **Proto C**, Vitali M, Macerelli M, Agustoni F, Indini A, Platania M, Zilembo N, Garassino MC, Di Guardo L, Del Vecchio M, Magni M, Sinno V, Seregini E, Di Nicola M, de Braud F. Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more? *Ann Oncol* 2015 26 (6). (Poster).
30. **Proto C**, Lo Russo G, Macerelli M, Vitali M, Agustoni F, Platania M, Zilembo N, Ganzinelli M, Tiseo M, Pasello G, Gallucci R, Cona MS, Botta L, Trama A, de Braud F, Garassino MC, Signorelli D. Lume Trial: searching for survival prognostic factors in malignant pleural mesothelioma. *Ann Oncol* 2015 26 (6). (Poster)
31. Lo Russo G, Macerelli M, **Proto C**, Vitali M, Signorelli D, Gallucci R, Platania M, Agustoni F, Zilembo N, Ganzinelli M, Raimondi A, Trama A, de Braud F, Garassino MC. Absence of standard in the management of Thymic Epithelial Tumors. *Ann Oncol* 2015 26 (6). (Poster)
32. Picone A, Franchina T, Russo A, **Proto C**, Raiti F, Buda C, Chiofalo G, Ferraro G, Picciotto M, Scimone A, Toscano G, Zanghì M, Adamo V. Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis. *J Clin Oncol* 32, 2014 (suppl; abstr e19164), *ASCO 2014*
33. Chiofalo G, Toscano G, berenato R, Smiroldo V, Noto L, **Proto C**, Buda C, Giuffrè G, Adamo V. Correlation between biological agent based regimens as first-line treatment and outcomes in patients with Kras wild type metastatic colorectal cancer (mCRC). *Suppl Tumori* 2013; S25 (abstr. A49).
34. Ferraro G, **Proto C**, Del re C, Agostino R, Zanghì M, Buda C, Ricciardi GRR; Adamo V. Correlation between serum magnesium levels and skin toxicity during cetuximab treatment

- squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. *Suppl Tumori* 2013. S33-34 (abstr B15)
35. T Franchina, A Russo, **C Proto**, G Chiofalo, M Picciotto, A Scimone, G Toscano, R Berenato, L Noto, V Adamo. Impact of erlotinib activity on overall survival in non small cell lung cancer patients: Is the post progression survival a new paradigm? Abstract ASCO 2013
 36. Franchina T, Bronte G, Savio G, Ferraro G, **Proto C**, Berenato R, Noto L, Chiofalo G, Russo A, Adamo V. New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. *Suppl Tumori* 2012; 13 (3):S85-86 (abstr D23). *XIV AIOM*
 37. Franchina T, Amodeo V, **Proto C**, Bronte G, Savio G, Russo A, Toscano G, Russo A, Adamo V. Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer. *Poster alla III CIOT 2012*
 38. Caristi N, Franchina T, **Proto C**, Chiofalo G, Toscano G, Scimone A, Zanghi M, Berenato R, Briguglio R, Denaro N, Noto L, Adamo V. Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. *J Clin Oncol.* 2011; 29 (suppl; abstr e18063)
 39. Franchina T, Caristi N, **Proto C**, Chiofalo G, Toscano G, Ricciardi G, Colonesi F, Caccamo D, Ientile R, Adamo V. Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients' outcome and correlation with p53 codon 72 mutations. *J Thorac Oncol.* 2011; 6(6, suppl 2) abstract P2.054. S955. *Poster 14th WCLC IASLC*
 40. Franchina T, **Proto C**, Noto L, Chiofalo G, Ferraro G, Picciotto M, Adamo V. Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. *Suppl Tumori* 2011; 11 (2):S83 (abstr. D67).
 41. Franchina T, Scimone A, Ferraro G, Garipoli C, Zanghi M, Berenato R, Briguglio R, Noto L, **Proto C**, Adamo V. Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors? *Suppl Tumori* 2010; 10 (1):S74-75 (abstr D43) *Poster XII AIOM*

Papers:

1. Galli G, Triulzi T, **Proto C**, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G. Association between Antibiotic-Immunotherapy Exposure Ratio and outcome in metastatic Non Small Cell Lung Cancer. *Lung cancer.* Published online: April 8, 2019
2. Platania M, Pasin F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vatterni E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, **Proto C**, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lorusso G, Tuzi A, Gallucci R, cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: the MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer* 132 (2019) 12-23
3. Fucà G, Galli G, Poggi M, Lo Russo G, **Proto C**, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open.* 2019 Feb 27;4(1):e000457.
4. **Proto C**, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treat Rev.* 2019 Mar 28;75:39-51.
5. Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, **Proto C**, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R,

- Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. *Lung Cancer*. 2019 Mar;129:35-40.
6. Boeri M, Milione M, **Proto C**, Signorelli D, Russo GL, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clin Cancer Res*. 2019 Jan 7. *(First name, equal contribute to the first author)*
 7. Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, **Proto C**, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. *Clin Lung Cancer*. 2018 Nov 20.
 8. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators: Alloisio M, Apolone G, Ardizzoni A, Benvenuti M, Berruti A, Breda C, Buzzoni C, Calabrese F, Caraceni A, Cardillo G, Casadio C, Cassi E, Caterino M, Cecere FL, Chiti A, Crippa A, Curcio C, De Braud F, De Pas T, Di Tommaso L, Evoli A, Facciolo F, Galli G, Lopez I, Lo Russo G, Luisella S, Luzzi L, Mantovani C, Marchianò A, Margaritora S, Monaco R, Morandi U, Novellino L, Piras MT, Porcu L, Priola A, **Proto C**, Battista Ratto G, Rena O, Rinaldi S, Roca E, Rocco G, Ruffini E, Signorelli D, Solli P, Spaggiari L, Stefani A, Veltri A, Vespro V, Zilembo N. vBest practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). *Cancer Treat Rev*. 2018 Dec;71:76-87.
 9. Fucà G, Galli G, Poggi M, Lo Russo G, **Proto C**, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Target Oncol*. 2018 Dec;13(6):795-800.
 10. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMPower133 Study Group: ... **Proto C**... First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018 Dec 6;379(23):2220-2229.
 11. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, **Proto C**, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clin Cancer Res*. 2019 Feb 1;25(3):989-999.
 12. Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, **Proto C**, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. *Eur J Cancer*. 2018 Sep;100:126-134.
 13. Galli G, Corrao G, Imbimbo M, **Proto C**, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer*. 2018 Jan;115:135-142.
 14. Vitali M, Ripamonti CI, Roila F, **Proto C**, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol*. 2017 Oct;118:7-14.
 15. **Proto C**, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. *Tumori*. 2017 Jul 31;103(4):325-337.
 16. Lo Russo G, Imbimbo M, Corrao G, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases. *Oncotarget*. 2017 Apr 26.
 17. Facchinetti F, **Proto C**, Minari R, Garassino M, Tiseo M. Mechanisms of Resistance to

- Target Therapies in Non-small Cell Lung Cancer. *Handb Exp Pharmacol*. 2017 Mar 23.
18. **Proto C**, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the treatment of Central Nervous System metastases from Non Small Cell Lung Cancer. The present and the future. *Translational Lung Cancer Research* (review)
 19. Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregini E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumor Biol*. 2016 July 15. (review)
 20. Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, **Proto C**, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC. Small-cell lung cancer: clinical management and unmet needs. New perspectives for an old problem. *Curr Drug Targets*. 2016 May 2 (review)
 21. Pelosi G, Pelleggrinelli A, Fabbri A, Tamborini E, Perrone F, Settanni G, Busico A, Piccioni B, Testi MA, Militti L, Maisonneuve P, Valeri B, Sonzogni A, **Proto C**, Garassino M, De Braud F, Pastorino U. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. *Virchows Arch*. 2016 Apr 7
 22. Lo Russo G, Pusceddu S, **Proto C**, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Marina Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. *Tumour Biol*, 2016. (review).
 23. Pusceddu S, Lo Russo G, Macerelli M, **Proto C**, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. *Crit Rev Oncol Hematol* 2016. (review)
 24. Lo Russo G, **Proto C**, Garassino MC. Afatinib in the treatment of squamous Non-Small Cell Lung Cancer: a new frontier or an old mistake? *TLCR*. 2016 Oct 28 (editorial) (**First name, equal contribute to the first author**).
 25. Signorelli D, Macerelli M, **Proto C**, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? *Tumori* 2016;102(1):18-30.(review)
 26. Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. (Collaborators: Barni S, Maiello E, Di Maio M, Crinò L, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Barni S, Petrelli F, Raisi E, Frassoldati A, Santini A, Longo P, Botta M, Oletti MV, Biaggi G, Muzio A, Gattoni E, Giaretto L, Bertoldo E, Perroni D, Facilissimo I, Evangelisti L, Del Conte A, Ius A, Numico G, Cristofano A, Barè C, Ballardini P, Margutti G, Tiseo M, Camisa R, Rapacchi E, Bartolotti M, Cortinovis D, Gila MP, Grossi F, Donato C, Dal Bello MG, Rijavec E, Barletta G, Genova C, Diaz N, Sini C, Boni C, Zanelli F, Gnoni R, Stridi G, Magnani E, Gervasi E, Fanello S, Lonati V, Petrelli F, Cremonesi M, Del Conte G, Dicorato A, Caffo O, Murgia V, Veccia A, Giordano M, Gilardoni M, Luchena M, Vattermi E, Barbieri F, Marra L, Pettrelli E, Mazzocchi MG, Meriggi F, Spaggiari L, Solli P, Martoni AA, Melotti B, Esposti CD, Amadori D, Monti M, Milandri C, Rosti G, Bertolin M, McMahon L, Mauri M, Martelli O, Di Lieto M, Ricasoli M, Recchia F, Di Blasio A, Candeloro G, Baldini E, Pellegrini M, Coppi E, Cirigliano G, Tursi M, Iacobelli S, Intelli L, Giampietro J, Tinari N, Cascinu S, Berardi R, Lucarelli A, Pierantoni C, Onofri A, Burattini M, Crinò L, Marchetti F, Chiari R, Bennati C, Di Costanzo F, Cecere F, Ranchicchio CP, Mazzoni F, Cristina L, Travagliato L, Rinaldi A, Bruno S, Adamo V, Franchina T, **Proto C**, Maiorino L, Musicò M, Ortu S, Putzu C, Galetta D, Catino A, Rizzi D, Palomba G, Capuano G, Bellocco G, Nardi M, Giannicola R, Falzea A, Carteni G, Fiorentino R, Otero M, Planeta A, Giovanis P, Testore F, Ceste M, Dongiovanni D, Mencoboni M, Tonini G, Intagliata S, Potestà C, Maio M, Calabrò L, Annesi D, Bordonaro R, Longhitano L, Contu A, Contu M, Pazzola A, Lorusso V, Petrucelli L, Romano G, Gambino A, Agostara B, Savio G, Signorini A, Turrini M, De Signoribus G, Brugni M, Cappuzzo F, Lani E, Landi L, Minuti G, D'Incecco A, Palazzo S, Turano S, Biamonte R, Manfredi C, Iacono C, Licitra S, Ori A, Rizzoli S, Sala S, Sgarbi S, Simoni L, Trevisan F, Fiori G). Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung*

Cancer. 2015 Nov;90(2):234-42.

27. Ricciardi GR, **Proto C**, Ferraro G, Adamo V. Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient. *Future Oncol*. 2014 Dec;10(15):2417-22. (clinical case)
28. Franchina T, Adamo B, Ricciardi GR, Caristi N, Agostino RM, **Proto C**, Adamo V. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. *Cancer Biol Ther* 2012 May;13(7):472-6. (clinical case)

PRESENTAZIONI ORALI

- *San Benedetto del Tronto, 10/11/18 Marcangolo 2018, "Prima o poi dobbiamo tutti affrontare la scelta tra ciò che è giusto e ciò che è facile..."*
- *Palermo, 02/10/2018 Salute donna Onlus- Salute Uomo Tumore al polmone e Tumori della testa e del collo. News in immuno-oncologia: overview degli studi clinici e prospettive terapeutiche nel tumore polmonare*
- *Bergamo, 04-05/05/18 Le nuove sfide professionali nell'immunoterapia dei tumori polmonari, Scenario 1: Tossicità Polmonare*
- *Messina, 12-13/10/2017 2nd Sicilian Oncologist day: linee guida AIOM, appropriatezza e medicina di precisione*
- *Siena, 05-07/10/2017 XV NIBIT Meeting Anti-PD-1 mAbs for the treatment of NSCLC patients*
- *Milano, 09/02/2016. Tutto quello che avresti voluto chiedere.*
- *Catania, 1-2/04/2016. Focus sul carcinoma del polmone: assistenza e ricerca*
- *Milano, 19/4/2016. Fondazione IRCCS Istituto Nazionale dei Tumori. Insieme per le neoplasie toraciche.... Tra sogno e realtà.*
- *Messina 14/04/2013 SCCHN: decidere, sostenere, curare insieme.*
- *Messina, Hospital meetings*

STUDI CLINICI

Partecipazione a protocolli scientifici in qualità di Subinvestigator

1. CHECKMATE 017: An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
2. BIRCH GO28754: A phase II, multicenter, single-arm study of MPDL3280A in patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer.
3. CDK0125A-006: Phase II Study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy
4. CDK0125A-007: Phase II study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy
5. AURA3: A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (**FDA Inspection**)
6. ALEX BO28984: Randomized Multicenter Phase III Open Label Study Of Alectinib Versus crizotinib In Alk-Inhibitor Treatment Naïve naplastic Lymphoma Kinase-positive Advanced Non-Small Cell Lung Cancer
7. ASCEND 7: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges
8. APOLLO: studio osservazionale prospettico per valutare l'impatto prognostico/predittivo di fattori correlati alla risposta immunitaria nel carcinoma del polmone non a piccole cellule
9. ATLANTIC: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based
10. ARCTIC: A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic

Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements

11. HANMI HM-EMSI-202: A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
12. E-3810-II-02 A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF-related genetic alterations
13. BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
14. TRANSCAN BIO-Rare K-RAS mutations and DNA repair functions in NSCLC
15. A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
16. KEYNOTE -024: A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
17. CC-486-NSCL-001: A phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic non-small cell lung cancer
18. CHECKMATE CA209-227: An Open-Label, Randomized Phase 3 Trial of Nivolumab versus platinum doublet chemotherapy and Nivolumab plus Ipilimumab versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
19. PACIFIC : A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
20. GO29432: A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-Pd1 Antibody) Compared With Gemcitabine+Cisplatin Or Carboplatin For Pd-L1-Selected, Chemotherapy Naïve Patients With Stage Iv Squamous Non-Small Cell Lung Cancer
21. GO30081: a phase I/III, randomized, double-blind, placebo-controlled study of carboplatin plus etoposide with or without atezolizumab (anti PD-L1 antibody) in patients with untreated extensive-stage small cell lung cancer
22. CA209-331: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy
23. JAVELIN LUNG 200: A Phase III open-label, multicenter trial of MSB0010718C versus docetaxel in subjects with PD-L1 positive non-small cell lung cancer that has progressed after a platinum-containing doublet.
24. MANILA: Maintenance Metronomic Per Os Navelbine In Advanced Nsclc Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase Ii Study Ma.Ni.La. Trial
25. STUDIO LUME: Long sUrvivors in pleural MEsothelioma
26. OPEL-OTSUKA: A prospective, observational study measuring sodium improvement and outcomes in cancer patients treated for moderate to severe hyponatremia secondary to SIADH
27. PEARLS: Immunotherapy with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy study
28. KEYNOTE-189: A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects
29. MYSTIC : A Phase III Randomized, Open-Label, Multi-Center, Global Study of First-Line MEDI4736 in Combination with Tremelimumab and MEDI4736 Monotherapy

- Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
30. BAY 94-9343 / 15743: A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy"
 31. An open label Phase Ib dose escalation study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and maximum tolerated dose of anetumab ravtansine in combination with pemetrexed 500 mg/m² and cisplatin 75 mg/m² in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer
 32. CASPIAN: A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
 33. RAMES: Studio di Fase II randomizzato, doppio cieco con placebo, multicentrico, di confronto con Gemcitabina in associazione a Ramucirumab verso Gemcitabina+ placebo, nel trattamento di seconda linea del mesotelioma pleurico maligno.
 34. BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer
 35. A phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK-positive non small cell lung cancer
 36. A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer
 37. PEOPLE: Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%) PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)
 38. FAME: Exploiting metformin plus/minus cyclic Fasting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-inactivated lung adenocarcinoma: the FAME trial
 39. PROGETTO TIMOMA : CREAIONE DI UN DATABASE GENETICO PER LO STUDIO DELLE NEOPLASIE EPITELIALI TIMICHE. Studio Osservazionale Prospettico Per Valutare L' Impatto Prognostico/Predittivo Di Fattori Correlati Alla Risposta Immunitaria Nel Carcinoma Del Polmone Non A Piccole Cellule
 40. BIOTET: studio osservazionale su campioni biologici di pazienti con carcinoma timico o timoma
 41. RELEVANT: improving treatment strategies in thymic epithelial tumors: a Tyme collaborative effort
 42. IND227: Studio randomizzato di fase 2-3 con pembrolizumab in pazienti affetti da mesotelioma pleurico maligno avanzato
 43. LuCApp: A mobile supportive care app for patients with metastatic lung cancer: a pilot randomized controlled trial. The Lung Cancer App (LuCApp) study
 44. KEYNOTE-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC)
 45. GO40241-IMPOWER 030: a phase III, double-blinded, multi center, randomized study evaluating the efficacy and safety of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer
 46. CACZ885T2301: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
 47. POLARIS: Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
 48. Studio osservazionale retrospettivo/prospettico per valutare l'impatto prognostico/predittivo di fattori correlati alla risposta nel mesotelioma pleurico maligno

49. VISION: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations
50. A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
51. Studio retrospettivo osservazionale multicentrico su pazienti con carcinoma polmonare non a piccole cellule EGFR mutato o ALK riarrangiato con metastasi ossee
52. ZENITH20: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation
53. EXELIXIS: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
54. PACIFIC 6: A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer
55. STYLE: studio di fase 2 con sunitinib in pazienti affetti da timoma B3 e carcinoma timico, recidivato e/o metastatico, in seconda linea e successive
56. LUNG 037: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non small Cell Lung Cancer
57. 205801: A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
58. CLDK378A2X01B: An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
59. Alectinib compassionate Use Program for ALK- Positive NSCLC Patients
60. Ceritinib Compassionate Use Program for ALK- Positive NSCLC Patients
61. An Open Label, Multicenter, Single Arm Expanded Access Study of Brigatinib (AP26113) for Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC)
62. PF-06463922 (Lorlatinib) Named-Patient Early Access
63. An Early Access Programme for Durvalumab as Monotherapy for the Treatment of Adults with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (NSCLC) Whose Disease Has Not Progressed Following Platinum-based Chemoradiation Therapy

Ideazione e stesura protocolli scientifici

1. PEOPLE: Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%) PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)
2. APOLLO: studio osservazionale prospettico per valutare l'impatto prognostico/predittivo di fattori correlati alla risposta immunitaria nel carcinoma del polmone non a piccole cellule

CO-Principal investigator progetto di ricerca finalizzata 2016

Altered Hedgehog pathway in malignant pleural mesotelioma as source for new prognostic biomarkers and therapeutic targets

Partecipazione a corsi formativi all'estero su terapie cellulari

- Clinical Application of CAR T Cells 2017, MSKCC, November 16-17 2017, New York

Partecipazione a diversi convegni e corsi formativi in qualità di uditore

La sottoscritta è a conoscenza che, ai sensi dell'art. 76 DPR 28/12/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto D. Lgs. 196/03.

LUOGO E DATA Milano, 03/06/2019

F. to
Claudia Proto

A handwritten signature in black ink, appearing to read 'Claudia Proto', with a large, stylized loop at the end.